• Jiji

  • SHARE

Japan’s Ricoh Co. said Tuesday that it will enter the drug contract development and manufacturing business by acquiring a U.S. startup engaged in advanced medicine.

Ricoh hopes that its artificial intelligence and other technologies will help support the development of drugs using messenger RNA and induced pluripotent stem, or iPS, cells. The company expects the business to become a main revenue source on a par with its office equipment business.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)